STAAR Surgical Company - Asset Resilience Ratio
STAAR Surgical Company (STAA) has an Asset Resilience Ratio of 6.93% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See STAAR Surgical Company working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how STAAR Surgical Company's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see STAAR Surgical Company total assets.
Liquid Assets Composition Over Time
This chart breaks down STAAR Surgical Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore STAAR Surgical Company long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $32.91 Million | 6.93% |
| Total Liquid Assets | $32.91 Million | 6.93% |
Asset Resilience Insights
- Limited Liquidity: STAAR Surgical Company maintains only 6.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
STAAR Surgical Company Industry Peers by Asset Resilience Ratio
Compare STAAR Surgical Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Tinavi Medical Technologies Co Ltd
SHG:688277 |
Medical Instruments & Supplies | 2.05% |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
Daxor Corporation
NASDAQ:DXR |
Medical Instruments & Supplies | 65.10% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Annual Asset Resilience Ratio for STAAR Surgical Company (2001–2025)
The table below shows the annual Asset Resilience Ratio data for STAAR Surgical Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.45% | $34.39 Million | $461.62 Million | -9.50pp |
| 2024-12-31 | 16.94% | $86.33 Million | $509.52 Million | +9.23pp |
| 2023-12-31 | 7.71% | $37.69 Million | $488.69 Million | -22.17pp |
| 2022-12-31 | 29.88% | $125.16 Million | $418.82 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $345.78 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $67.93 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $65.44 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $62.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $58.91 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $61.93 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $54.76 Million | -- |
| 2011-12-31 | 0.26% | $129.00K | $49.01 Million | -0.06pp |
| 2010-12-31 | 0.33% | $133.00K | $40.59 Million | -12.28pp |
| 2009-12-31 | 12.60% | $7.40 Million | $58.68 Million | +12.26pp |
| 2008-12-31 | 0.34% | $179.00K | $52.58 Million | +0.06pp |
| 2007-12-31 | 0.28% | $150.00K | $54.18 Million | -0.04pp |
| 2006-12-31 | 0.31% | $150.00K | $47.77 Million | -9.55pp |
| 2004-12-31 | 9.86% | $5.12 Million | $51.97 Million | +6.82pp |
| 2001-12-31 | 3.04% | $2.00 Million | $65.81 Million | -- |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorde… Read more